Table 1.
|
|
|
|
|
|
|
|
|
Drv concentrations (ng/ml) |
|
---|---|---|---|---|---|---|---|---|---|---|
Patient number | Visit number | Sex | Age | CD4 cell count(×106/liter) | Plasma VL (log10 copies/ml) | CSF VL (log10 copies/ml) | Antiretroviral treatment in addition to drv/r | Time on ART(weeks) | Plasma | CSF |
1 | 1 | m | 57 | 320 | 2.51 | <1.30 | zdv + 3TC + abc + T20 + ral | 13.0 | 2680 | 34.9 |
2 | m | 57 | 110 | <1.30 | <1.30 | zdv + 3TC + abc + ral | 43.5 | 8550 | 96.5 | |
2 | 1 | m | 46 | 160 | <1.30 | <1.30 | zdv + 3TC + abc + ral | 16.0 | 3870 | 25.6 |
2 | m | 46 | 190 | <1.30 | <1.30 | zdv + 3TC + abc + ral | 66.0 | 1800 | 19.6 | |
3 | 1 | m | 61 | 430 | 3.73 | <1.30 | zdv + 3TC + abc + T20 | 12.0 | 3210 | 33.5 |
2 | m | 61 | 370 | 1.82 | <1.30 | zdv + 3TC + abc + T20 | 50.0 | 6740 | 53.8 | |
4 | 1 | m | 43 | 80 | <1.30 | <1.30 | zdv + 3TC + abc + ral | 20.5 | 4060 | 35.5 |
2 | m | 43 | 140 | <1.30 | <1.30 | zdv + 3TC + abc + ral | 56.0 | 3990 | 23.5 | |
5 | 1 | f | 22 | 0 | 5.20 | 5.66 | zdv + 3TC + abc + ral | 0.5 | 12900 | 212.0 |
6 | 1 | m | 49 | 38 | 4.05 | <1.30 | zdv + 3TC + tdf + ral | 0.9 | 9120b | 43.9b |
2 | m | 49 | 92 | 2.66 | <1.30 | zdv + 3TC + tdf + ral | 4.0 | 3770 | 28.7 | |
7 | 1 | m | 50 | 133 | 4.10 | 4.00 | tdf + ftc + ral | 1.0 | 4590 | 15.9 |
2 | m | 50 | 140 | 2.35 | 1.32 | tdf + ftc + ral | 4.9 | 2820 | 20.1 | |
8 | 1 | m | 54 | 168 | 2.38 | <1.30 | zdv + 3TC + abc | 2.5 | 3550 | 64.8 |
VL, viral load; ART, antiretroviral treatment; m, male; f, female; zdv, zidovudine; 3TC, lamivudine; abc, abacavir; drv/r, darunavir/ritonavir; T20, enfuvirtide; ral, raltegravir; tdf; tenofovir; ftc, emtricitabine.
Sampling time unknown.